Solventum Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SOLV research report →
Range $35 – $113
Price Chart
About the company
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.
- CEO
- Bryan C. Hanson
- IPO
- 2024
- Employees
- 20,584
- HQ
- Eagan, MN, US
Get TickerSpark's AI analysis on SOLV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $14.36B
- P/E
- 96.70
- Fwd P/E
- 11.66
- PEG
- -1.08
- P/S
- 1.79
- P/B
- 3.06
- EV/EBITDA
- 24.28
- Div Yield
- 0.00%
- Gross Margin
- 54.27%
- Op Margin
- 24.60%
- Net Margin
- 1.91%
- ROE
- 3.18%
- ROIC
- 16.61%
Latest fiscal year · YoY change
- Revenue
- $8.32B+0.9%
- Gross Profit
- $4.45B-3.1%
- Op Income
- $2.18B
- Net Income
- $1.56B+224.8%
- EPS
- $8.94+222.7%
- OCF Growth
- -68.9%
- FCF Growth
- -101.2%
- 52W High
- $94.16
- 52W Low
- $62.38
- 50D MA
- $87.27
- 200D MA
- $79.05
- Beta
- 0.75
- RSI (14)
- 42
- Avg Volume
- 1.04M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Solventum said Q3 was solid despite an ERP cutover, with organic growth and EPS above plan, while separation is now more than 90% complete and margin/cash outlook remains constructive.· November 5, 2026
- Q3 sales were $1.95 billion, down 7% reported and down 2.8% organically; normalized organic growth was about 4% after ERP timing and SKU rationalization effects.
- Gross margin was 57.1%, up 120 bps year over year, and EPS was $1.45, including about $0.35 of impact from the Q2 ERP-related advanced-order reversal.
- The company said separation from 3M is now more than 90% complete, with the risky structural work largely done and remaining TSA exits expected to run through 2027.
- Management raised full-year 2026 EPS guidance to $7.20 to $7.30 and now expects full-year gross margin of about 57% and operating margin toward the high end of 22.2% to 22.7%.
- The HIS separation is still in process, with management prioritizing debt paydown first and shareholder returns with remaining proceeds.
Q3 2026 sales were $1.95 billion, down 7% reported and down 2.8% organically; foreign currency added 30 bps, while acquisitions/divestitures were a 450 bps headwind. Normalized organic growth was about 4% after reversing $125 million of ERP-related advanced orders and accounting for 90 bps of SKU rationalization headwinds. Gross margin was 57.1%, up 120 bps year over year. Operating income was $387 million and operating margin was 19.9%, down 70 bps from 20.6% a year ago. EPS was $1.45, including about $0.35 of impact from the ERP-related order reversal. Free cash flow increased by $97 million in the quarter; excluding separation and portfolio optimization costs, FCF would have been $334 million. For full-year 2026, Solventum now expects organic sales growth toward the high end of its 2.5% to 3% range, full-year gross margin of approximately 57%, operating margin toward the high end of 22.2% to 22.7%, EPS of $7.20 to $7.30, and free cash flow of $200 million to $300 million.
Bryan Hanson framed the quarter as proof that the company can execute through major operational complexity, calling the ERP cutover the largest and most complex in Solventum’s history and saying the team still delivered on revenue, margin, and free cash flow. He emphasized that separation from 3M is now more than 90% complete, that the risky structural work is largely behind them, and that the company is transitioning to a more focused RemainCo with stronger growth and margin potential. His tone was confident and upbeat, especially around the growth-driver portfolio, the Acera acquisition, and the V.A.C. opportunity.
Wayde McMillan highlighted the financial details: $1.95 billion in sales, 57.1% gross margin, $387 million of operating income, 19.9% operating margin, and $1.45 EPS. He said the company ended Q3 with $451 million in cash and equivalents and $4.6 billion of net debt, while free cash flow benefited from tariff refunds and underlying generation despite separation costs. He also said the renegotiated supply agreement with 3M eliminates a step-up in product costs scheduled for April 2027, removing a potential 100 bps gross margin headwind that could have started in Q3 2027. On capital allocation, he reiterated that proceeds from any HIS separation would first support debt paydown to maintain investment-grade ratings, with most of the remainder returned to shareholders.
Analysts focused on the implied Q4 organic growth rate, margin bridge into next year, and how to think about value creation versus dilution from the planned HIS separation. Management said the raised guide to the high end implies performance closer to 4% ex-SKU exits and that momentum should continue into 2027, aided by Acera. On margins, they said the business is still on track to expand next year even after the tariff refund normalizes, and that the 3M supply agreement resolution strengthens confidence. On Acera, Bryan said the new 510(k) clearance for combined use with V.A.C. is commercially important because it enables co-marketing, but it confirms rather than changes the growth assumptions already embedded in the deal.
The call suggested Solventum is exiting a heavy execution period with separation largely behind it, a more streamlined supply chain, and a clearer operating setup. Management sounded confident that core growth drivers, new products, and Acera can support continued organic growth and margin expansion, while the 3M supply agreement removes a future gross margin headwind.
The near-term results still reflect ERP-related timing noise, including the reversal of $125 million of advanced orders, and management noted the quarter was not seamless. The HIS separation introduces modeling uncertainty, including roughly 400 bps of annualized net operating margin dilution on a standalone basis, and the company still has remaining TSA exits and rebranding work to finish through 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 84.6%
- Shares Outstanding
- 169.96M
- Float Shares
- 143.73M
of shares held by institutions
908 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for SOLV, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 1, 26 | Filing → |
| French HillHouse · AR02 | Sell | Dec 31, 25 | Filing → |
| Ronald Lee WydenSenate · OR | Sell | Feb 6, 25 | Filing → |
| Julie JohnsonHouse · TX32 | Sell | Jan 15, 25 | Filing → |
| Thomas Hawley TubervilleSenate · AL | Buy | May 3, 24 | Filing → |
| Gary C. PetersSenate · MI | Sell | May 14, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 17.03M | ▼ 94.66K |
| Independent Franchise Partners Llp | 15.67M | ▼ 497.85K |
| Blackrock, Inc. | 9.56M | ▼ 205.09K |
| Vanguard Capital Management LLC | 9.48M | ▼ 147.81K |
| Trian Fund Management, L.P. | 8.24M | 0 |
| Davis Selected Advisers | 6.41M | ▲ 106.59K |
| Vanguard Portfolio Management LLC | 6.20M | ▼ 126.58K |
| State Street Corp | 5.61M | ▼ 24.25K |
| Geode Capital Management, LLC | 4.96M | ▲ 46.08K |
| Boston Partners | 3.58M | ▼ 460.05K |
| Invesco Ltd. | 3.20M | ▼ 109.39K |
| Dimensional Fund Advisors LP | 2.52M | ▲ 704.91K |
Held by 871 ETFs
Biggest fund positions in SOLV by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Knight Heather | other | 26,250 |
| Nov 17, 26 | Knight Heather | other | 26,250 |
| Nov 17, 26 | Knight Heather | other | 11,629 |
| Sep 1, 26 | Hanson Bryan C | other | 67,261 |
| Sep 1, 26 | Hanson Bryan C | other | 26,468 |
| Sep 1, 26 | Hanson Bryan C | other | 67,261 |
| Aug 17, 26 | Zieselman Neil Craig | other | 6,911 |
| Aug 10, 26 | Zieselman Neil Craig | other | 0 |
| May 15, 26 | ALBAN CARLOS | other | 3,300 |
| May 15, 26 | COX CARRIE SMITH | other | 4,848 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SOLV coverage
Recent articles, reports, and earnings notes.
No research on SOLV yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SOLV report →Solventum (SOLV) Boasts Earnings & Price Momentum: Should You Buy?
zacks.com · Nov 18
SOLV Energy Highlights Growing Customer Demand for Full-Lifecycle Infrastructure Partnerships at RE+ 2026
globenewswire.com · Nov 16
SOLV Energy Q3 Earnings Call Highlights
marketbeat.com · Nov 12
SOLV Energy, Inc. (MWH) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Solventum (SOLV) is a Top-Ranked Momentum Stock: Should You Buy?
zacks.com · Nov 12
Solventum Q3 Earnings Call Highlights
marketbeat.com · Nov 8
SOLV Q3 Earnings Beat Estimates Despite ERP-Related Revenues Decline
zacks.com · Nov 6
Solventum Corporation (SOLV) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.